Compositions comprising nebivolol
View Patent ↗Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
1. A method of treating hypertension comprising administering to a subject in need thereof a composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof and between about 1 mg to about 1200 mg of at least one other cardiovascular active agent selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof, wherein the effectiveness of the composition when administered to the subject is greater than treatment with nebivolol or a cardiovascular active agent selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof administered alone.
2. A method of treating a hypertension comprising administering to a subject in need thereof a composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof, and between about 1 mg to about 1200 mg of an angiotensin II receptor antagonist (ARB), wherein the ARB is selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof, wherein the treatment is at least 10% more effective than treatment with nebivolol or an ARB selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof administered alone.
3. The method of claim 1 wherein the cardiovascular active agent is olmesartan or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 wherein the cardiovascular active agent is valsartan or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 wherein the cardiovascular active agent is losartan or a pharmaceutically acceptable salt thereof.
6. The method of claim 2 wherein the ARB is olmesartan or a pharmaceutically acceptable salt thereof.
7. The method of claim 2 wherein the ARB is valsartan or a pharmaceutically acceptable salt thereof.
8. The method of claim 2 wherein the ARB is losartan or a pharmaceutically acceptable salt thereof.
9. A method of treating hypertension comprising administering to a subject in need thereof a composition comprising between about 0.125 mg to about 40 mg nebivolol or a pharmaceutically acceptable salt thereof and between about 1 mg to about 1200 mg of a cardiovascular active agent selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof wherein the composition provides a higher therapeutic index than nebivolol or a cardiovascular active agent selected from the group consisting of valsartan, losartan, olmesartan, or a pharmaceutically acceptable salt thereof administered alone.
10. The method of claim 9 wherein the cardiovascular active agent is olmesartan or a pharmaceutically acceptable salt thereof.
11. The method of claim 9 wherein the cardiovascular active agent is valsartan or a pharmaceutically acceptable salt thereof.
12. The method of claim 9 wherein the cardiovascular active agent is losartan or a pharmaceutically acceptable salt thereof.